+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the combined use of finerenone and empagliflozin compared to usual care to assess their safety and effectiveness in patients hospitalized with heart failure. This international, randomized, controlled, open-label trial aims to study an early, intensive management approach for heart failure treatment. Participants will be assigned to receive either the combination of oral finerenone plus oral empagliflozin or usual care. The study focuses on treatment during hospitalization and shortly after, comparing these approaches to understand the clinical benefits and risks over a six-month period. During the trial, participants will be monitored for clinical outcomes including serious adverse events and events leading to treatment discontinuation. Researchers will measure heart failure events, symptom changes using the Kansas City Cardiomyopathy Questionnaire, and overall survival up to six months. Safety and efficacy data will be collected throughout the study period ending in November 2027.

Age: 18Years +All GendersPhase 3
140 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.

Age: 18Years +All GendersPhase 3
356 locations
S

Actively Recruiting

Researchers are evaluating finerenone compared to a placebo to assess the effectiveness and safety of treatment in patients with heart failure and reduced ejection fraction HFrEF who cannot tolerate or are not eligible for steroidal mineralocorticoid receptor antagonists sMRA. This international study is a randomized, double-blind, placebo-controlled trial focused on this specific group of heart failure patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study uses a parallel design and treatment will be monitored for up to about 30 months. During this time, researchers will track cardiovascular events, heart failure events, and any serious or adverse events leading to discontinuation of the study drug. Throughout the study, participants will undergo regular assessments including symptom questionnaires and monitoring for cardiovascular outcomes and safety. The main outcomes include the time to the first cardiovascular death or heart failure event and the number of serious adverse events. The study also tracks changes in symptom scores over six months and overall survival. Participants will be followed closely during treatment and after to understand both efficacy and safety.

Age: 18Years +All GendersPhase 3
176 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TAR-210 compared to intravesical chemotherapy in treating high-risk non-muscle-invasive bladder cancer HR-NMIBC. This Phase 3 study focuses on disease-free survival, which is the length of time participants live without signs or symptoms of cancer returning or worsening. The study targets patients with specific FGFR genetic alterations who have previously received BCG treatment but remain at high risk for cancer recurrence. Participants are randomly assigned to one of two groups Group A will have the investigational drug TAR-210 placed inside the bladder on Day 1 and continue treatment for about two years. Group B will receive intravesical chemotherapy with either mitomycin C or gemcitabine weekly for 4 to 6 doses, followed by monthly maintenance for up to one year, with an optional second year of maintenance depending on the investigators decision. All treatments are delivered directly into the bladder. Throughout the study, participants will have regular assessments including monitoring for cancer recurrence, progression, and overall survival for up to five years. Researchers will collect safety data such as adverse events and changes in laboratory tests and vital signs. Quality of life will be measured using specific questionnaires at multiple time points. The study involves ongoing visits and evaluations to closely observe treatment effects and participant well-being over the long term.

Age: 18Years +All GendersPhase 3
115 locations
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
E

Actively Recruiting

Researchers are evaluating the effects of therapeutic-dose heparin compared to usual care pharmacological thromboprophylaxis in patients hospitalized with community-acquired pneumonia CAP. The study focuses on the high incidence of hospitalizations due to CAP, which often leads to serious complications including thrombotic events that affect respiratory, cardiac, and other organs. This trial aims to explore whether therapeutic-dose heparin can improve outcomes by targeting inflammatory and thrombotic pathways, a strategy shown to help in COVID-19 but not yet studied in non-COVID-19 CAP. Participants are randomly assigned to one of two groups. One group receives therapeutic-dose low molecular-weight heparin LMWH or unfractionated heparin UFH daily for up to 14 days or until hospital discharge, whichever comes first. The other group receives the usual care thromboprophylaxis dose according to local practice, which is lower than the therapeutic dose. Treatments start as soon as possible after randomization. LMWH is preferred unless contraindicated, with dosing based on patient weight, while UFH may be used in cases of renal impairment. During the study, participants will be monitored for outcomes including survival at 30 days, bleeding events, thrombotic events, mechanical ventilation use, mortality at various timepoints, hospital-free days, and health-related quality of life. The study collects data up to 180 days after treatment. Safety monitoring includes tracking adverse events like bleeding and heparin-induced thrombocytopenia. Participation involves hospital stays expected to last at least 72 hours from randomization, with assessments throughout the treatment period and follow-up extending to 180 days.

Age: 18Years +All GendersPhase 3
68 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are investigating how blood flow restriction BFR can help improve recovery after intense resistance training, which often causes significant muscle stress and fatigue. This randomized clinical trial includes healthy men and women aged 18 to 35, aiming to compare different levels of BFR and a control group to find effective ways to speed up muscle recovery. Participants will be randomly assigned to one of four groups BFR using 80% of total occlusion pressure, BFR using 60% of total occlusion pressure, BFR using 10 mmHg pressure, or a control group resting without BFR. Each participant will undergo a muscle stress protocol followed by their allocated intervention applied continuously for 20 minutes. Assessments will be conducted immediately, and again at 24, 48, and 72 hours after exercise. During the study, participants will complete multiple evaluations including pain ratings, recovery perception, muscle strength and power tests, and muscle tone measurements using techniques like myotonometry and bioelectrical impedance analysis. The main outcomes focus on changes in muscle power, function, strength, soreness, and other recovery-related measures up to 72 hours after exercise. Participants will be monitored closely throughout the study period ending in late 2027.

Age: 18Years - 35YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Healthy Volunteer

Researchers are studying the effects of combining active recovery AR and blood flow restriction BFR on post-exercise recovery in amateur male runners aged 18 to 40 years who run faster than 530 minkm. The trial aims to find out if using both recovery techniques together improves outcomes compared to active recovery alone or complete rest. Thirty-four participants will be randomly assigned to one of three groups based on their running test performance. Participants will undergo baseline assessments and a muscle stress protocol before receiving their assigned recovery method. One group will do 10 minutes of active recovery with blood flow restriction applied by a pneumatic cuff set at 60% occlusion pressure. Another group will perform 10 minutes of active recovery without restriction, while the control group will rest completely for 10 minutes. Follow-up evaluations will occur immediately after exercise and at 24, 48, 72, and 96 hours post-exercise. During the study, participants will have various measures taken including muscle strength, aerobic capacity, muscle power, soreness, pain threshold, muscle tone, and heart rate variability. These assessments will help determine changes from baseline up to 96 hours after exercise. Participants will be informed about the study and must consent before joining. Their data may be shared with research partners or regulatory authorities as approved. The study is sponsored by Paulista University and approved by the relevant ethics committee.

Age: 18Years - 40YearsMALEPhase Not Applicable
1 location
S

Actively Recruiting

Healthy Volunteer

This observational study investigates how lifestyle habits and health characteristics, such as physical activity and excess weight, relate between parents and their children aged six years and older. Researchers aim to understand whether these habits and health factors are connected across different physical activity domains and intensities, including work or school activities, leisure time, and active commuting. The study also explores links between other habits like smoking, eating disorders, anxiety, depression, chronic diseases, and overweight status, considering the parents physical activity levels. The study involves no intervention or treatment instead, it observes children, adolescents, and at least one of their biological parents. Researchers collect data on physical activity using both objective and subjective measures, focusing on different intensities and domains. The study includes assessments of various health and lifestyle factors such as sedentary behavior, blood pressure, body measurements, bone density, mental health symptoms, quality of life, sleep quality, and eating habits, all measured at baseline. Participants will be evaluated through questionnaires, physical measurements, and health assessments. These include monitoring physical activity patterns, sedentary time, cardiovascular function, and psychological well-being. The primary outcomes are objective and subjective measures of physical activity. Secondary outcomes cover a broad range of health and lifestyle indicators. The studys duration and follow-up details are not specified, with data mainly collected at baseline to analyze the relationships between parents and childrens lifestyles and health.

Age: 6Years - 89YearsAll Genders
1 location
P

Actively Recruiting

Researchers are investigating how daily movement behaviors, including physical activity, sedentary time, and sleep, relate to the risk of atherosclerosis in adults with rheumatoid arthritis. This observational study aims to understand whether these behaviors alone or combined are linked to cardiovascular risk indicators and how changes over 12 months affect vascular health. Rheumatoid arthritis increases cardiovascular risk beyond traditional factors, making this research important for improving heart health management in this group. Participants will wear accelerometers for 7 continuous days to objectively measure movement behaviors and sleep. They will also complete health and lifestyle questionnaires. Cardiovascular health will be assessed through various tests including pulse wave velocity, blood pressure measurements, and imaging for atherosclerotic indicators. Follow-up assessments will occur 12 months after baseline to observe changes over time. Throughout the study, participants will undergo physical fitness tests, body composition measurements, blood tests for lipid and inflammatory markers, and comprehensive cardiovascular evaluations. Researchers will analyze data to explore relationships between movement behaviors and cardiovascular risk, using advanced statistical methods. The total participation spans baseline and a 12-month follow-up, aiming to provide insights for future lifestyle recommendations in rheumatoid arthritis care.

Age: 18Years - 65YearsAll Genders
1 location